RICHMOND PHARMACOLOGY LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared detailed trading and cash flow projections. For 2025, the directors have forecast continued growth in turnover and profits. Profits and positive cash flows are expected to December 2025 and for at least 12 months from the date of approval of these financial statements, with no additional debt or utilisation of facilities. Consequently, the directors have a reasonable expectation that the Company has adequate resources to continue to meet its liabilities as they fall due for a period of at least 12 months from the date of approval of these financial statements. They have therefore concluded that there is no material uncertainty about the ability of the Company to continue as a going concern and that is remains appropriate to continue to prepare the financial statements on a going concern basis.”

Group structure

1. RICHMOND PHARMACOLOGY LIMITED · parent
   1. Prefect Limited 100% · England and Wales · Dormant
   2. Richmond Pharmaceutical Services Limited 100% · England and Wales · Dormant
   3. Richmond Pharmacology GmBH 100% · Germany · No operating activities

Significant events

• “Performance was still impacted by the MHRA failure to adhere to its own statutory timelines for the review and approval of clinical studies. However, the impact dissipated over the year, leading to a very strong performance in the last 6 months of 2024, through increased revenue and management efficiency savings. The temporarily unfavourable/unpredictable MHRA approval times meant that work destined for Richmond and the UK, in general, was placed abroad during 2023/24.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -6.2%

  £23,188,143 → £21,745,142

• Cash

  -16.1%

  £417,641 → £350,592

• Net assets

  +4.4%

  £6,054,367 → £6,323,332

• Employees

  -11.5%

  218 → 193

• Operating profit

  +346.4%

  -£490,914 → £1,209,807

• Profit before tax

  +239.4%

  -£728,251 → £1,015,233

• Wages

  -12.2%

  £10,671,766 → £9,367,630

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers